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ABSTRACT
Introduction: What is the rate of injecting
patients with shoulder corticosteroid injections
to alleviate excessive stiffness and pain within
6 months after shoulder surgery?
Methods: Retrospective 10-year review of a
shoulder surgeon’s practice. Participants inclu-
ded 754 patients who had 945 non-arthroplasty
shoulder surgeries. Outcome measures included
the rate of injections, diagnoses, patient char-
acteristics, and efficacy via questionnaire.
Results: Approximately one in five patients
received a subacromial and/or glenohumeral
corticosteroid injection. Over 95% of patients
stated that the injections helped reduce shoul-
der pain and increased function 6 weeks
post-injection. Twenty-two percent of cases
(208/945) received glenohumeral and/or sub-
acromial injections. The 208 injected cases had
these diagnoses: rotator cuff tear (28% of
injected patients), subacromial impingement
(20%), glenohumeral instability (16%), sub-
acromial impingement with acromioclavicular
osteoarthritis (10%), adhesive capsulitis (7%),
SLAP lesion (5%), biceps tendinopathy (3%),
glenohumeral instability with subacromial
impingement (3%), proximal humerus fracture
(2%), calcific tendinitis (2%), and less common
conditions (4%). Diagnoses among those with
the highest rates of injected patients per diag-
nosis included: SLAP lesions (40%), calcific
tendinitis (40%), adhesive capsulitis (29%),
subacromial impingement (28%), proximal
humerus fracture (24%), rotator cuff tear (19%),
and glenohumeral instability (16%). Significant
differences (p\0.03) were found between
patients who did and did not receive injections
with respect to age (more likely younger
patients with cuff tear) and sex (more likely
female with subacromial impingement and
instability) but not for diabetes or arthroscopic
vs. open procedures.
Conclusion: This is the first study to establish
the rates of postoperative shoulder corticos-
teroid injections within the first 6 months after
various non-arthroplasty shoulder surgeries for
patients with high pain/stiffness. These data
will be useful for establishing guidelines for
using corticosteroid injections along with
physiotherapy.
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Pain and stiffness are often concurrent prob-
lems that impede the recovery of patients who
have had shoulder surgery despite being enrol-
led in a physiotherapy program. Surgeons
commonly administer corticosteroid injections
to help relieve the symptoms of these patients
and aid their progression through physiother-
apy, but this intervention has received little
study, and the rationale for the use of these
injections in the postoperative setting is largely
based on anecdotal evidence. Our main goal of
the present study is to establish our rates of
administering postoperative corticosteroid
injection treatments for our patients who had
non-arthroplasty shoulder surgery. We will then
use this information as baseline data for
designing prospective randomized trials to
assess their effectiveness when used in combi-
nation with physiotherapy to reduce shoulder
stiffness and/or pain when compared to control
and alternative treatment groups in the post-
operative setting.
The high level of pain experienced by
patients after the various types of shoulder
surgeries is well documented. For example, a
survey-based investigation of the severity of
pain following ambulatory surgery in 5703
patients showed that 30% (1712) experienced
moderate-to-severe postoperative pain. In the
patients with moderate-to-severe pain, 54% had
shoulder surgeries [1]. Surgery for rotator cuff
disease, subacromial impingement, gleno-
humeral instability, calcific tendinitis, and
other common shoulder conditions or injuries
can produce high and persistent pain levels that
increase the probability of developing excessive
postoperative stiffness in some patients [2–4].
While some reviews and meta-analyses show
that there can be highly variable outcomes
when subacromial and glenohumeral corticos-
teroid injections are used for alleviating pain
and/or stiffness for certain common shoulder
conditions [5–7], many studies support their
continued use in this context [8–12].
In the first 10 years of his private practice,
the senior author (JGS) and his colleagues
published papers wherein they reviewed the
literature on the varying effectiveness of these
injections in addition to overviewing the indi-
cations, dosages, administration techniques,
and appropriate use vs. misuse of corticosteroid
injections in the treatment of various shoulder
conditions [13–17]. However, we are not aware
of any published studies that have investigated
both the frequency with which corticosteroid
injections are given and the specific conditions
for which they are given within 6 months after
non-arthroplasty shoulder surgeries.
In our study we focused on this question:
What is the rate of injecting patients with
shoulder corticosteroid injections to alleviate
excessive stiffness and pain within 6 months
after shoulder surgery? In this context, we
hypothesized that postoperative corticosteroid
injections for excessive pain and/or stiffness
would be most commonly given in the follow-
ing circumstances because of their propensity to
result in excessive pain and/or stiffness: (1) after
procedures for rotator cuff tears, shoulder
instability, and calcific tendinitis [2, 18, 19], (2)
in procedures for diabetic patients [2, 20], and
(3) in open procedures when compared to
arthroscopic procedures [2, 21].
METHODS
Compliance with Ethics Guidelines
This study was reviewed and approved by the
Ethics Committee of Intermountain Healthcare
(no. 1024079, Salt Lake City, UT, USA). All
procedures followed were in accordance with
the Helsinki Declaration of 1964, as revised in
2013. The analysis used anonymous clinical
data that were obtained after each patient
agreed to treatment by written consent. Because
the study is retrospective, patients were not
aware that data related to their treatment and
management would be used for this study. For
full disclosures, the details of the study are
available from Intermountain Healthcare Insti-




We retrospectively reviewed medical records
from a 10-year period (January 2002 to January
2012) from one surgeon’s practice. During this
period approximately 40–60% of the surgeries
that the surgeon performed were for shoulder
and elbow conditions or injuries.
Participants
The 754 patients included in this study had 945
shoulder surgeries that excluded arthroplasty.
Table 1 shows the number and frequency of
male, female, and all patients within each
diagnostic/surgery group. We did not exclude
patients from the study due to age or diabetes.
Exclusion criteria included: revision shoulder
surgery, fracture nonunion or pseudoarthrosis,
stiffness caused by glenohumeral arthritis,
shoulder arthrodesis, congenital disorders with
impaired shoulder function, diagnostic shoul-
der arthroscopy, shoulder girdle motor control
deficits, postoperative neurologic complication
resulting in functional deficit of the shoulder,
more than one operation on the same shoulder
in the study period, previous shoulder arthro-
plasty, delayed wound healing, and infection or
suspicion of infection.
We also examined medical records of the 945
surgical cases that met the inclusion criteria for
corticosteroid injections given in the shoulder
region during the 6 months following their
shoulder surgery. The following information was
recorded: patient age, sex, body mass index (BMI),
diabetic history, medication use, and additional
medical history (including thyroid dysfunction,
Dupuytren’s disease, cerebral vascular accident,
myocardial infarction, cardiovascular disease, and
breast cancer treatment) [2, 22].
After surgery the following data were recor-
ded: type of operation, type of surgery (arthro-
scopic or open), dominant hand and right/left
shoulder operated on, range of motion imme-
diately before surgery, and septic, dermatologi-
cal, or other complications spanning for up to
1 year after surgery.
After surgery all patients were allowed ad li-
bitum use of oral NSAIDs as long as they were
tolerated and not medically contraindicated. All
patients received postoperative physiotherapy
using standardized protocols [23]. After being
discharged from formal physiotherapy, all
patients continued a self-directed home phys-
iotherapy program that continued for at least
6 months after their shoulder surgery.
Intervention
The senior author (JGS) administered all of the
corticosteroid injections, which were given with
the intent to alleviate excessive shoulder pain
and/or stiffness within 6 months after his
patient’s shoulder surgeries. The decision to
inject was based on patient-reported stiffness
(B60% full motion in shoulder flexion or
external rotation) and pain of at least moderate
intensity with activities of daily living and
during physiotherapy [24] as well as the
patient’s progress in physiotherapy and recov-
ery thereafter. This approach reflected the sur-
geon’s standard practice, which did not change
during the 10-year study period.
Most patients who received an injection
were placed into one of two general categories:
(1) mostly pain of moderate-to-severe intensity
during physiotherapy and (2) mostly stiffness,
with pain being less than moderate during
physiotherapy. A third category was created
(‘‘bursitis/inflammation’’) for patients who had,
compared to the other two categories, pain that
was more localized to the subacromial region.
All corticosteroid injections were adminis-
tered freehand by the senior author without the
use of fluoroscopy or any other image-guided
technology. The injections were given into the
subacromial (SA) space and/or the gleno-
humeral (GH) joint. Whether one or both
locations were injected depended on the senior
author’s examination and the specific location
of the surgery [e.g., subacromial region vs.
glenohumeral region (or both)]. If there was
excessive stiffness (B60% full motion in shoul-
der flexion or external rotation), then both
locations were injected. For all of the injections,
the skin was first prepped with alcohol swabs
and was allowed to dry. This was then followed




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































allowed to dry. Each injection included 4 cc of
1% lidocaine and 80 mg of methylprednisolone
acetate (Depo-Medrol injectable suspension;
Pfizer Inc., NY, USA); the same amounts were
used for the subacromial space and gleno-
humeral joint. Consequently, when both of
these locations were injected, the patient
received a total of 8 cc of 1% lidocaine and
160 mg of Depo-Medrol. These volumes are
consistent with conventional practice [13].
Additional details of the injection techniques
are described elsewhere [14].
Outcome Measures
The primary outcome measure in this study was
the diagnosis, and consequently the type of sur-
gery, for the patients who received shoulder
corticosteroid injections within 6 months after
surgery. Secondary outcomes included the
patient characteristics, pain relief, and their
overall assessment of how well the injections had
helped them. After receiving their injections, the
patients were seen in clinic at 4–6-week intervals
for at least three additional visits. At each fol-
low-up, the general effectiveness of the injection
in facilitating patients’ progress in physiotherapy
and their general improvement in shoulder
function were determined. Patients’ appraisals of
their improvement, failure to improve, or wors-
ening pain and/or stiffness were obtained from
their verbal reports and by a written report from
their physiotherapist. The efficacy of the injec-
tions between the 4–6-week and 8–12-week fol-
low-up visits was determined using patients’
responses to a questionnaire regarding their
general improvement in pain and function. The
possible responses included: (1) worse, (2) not
improved (but not worse), or (3) better. The latter
group (‘‘better’’) had three responses that were
printed on a horizontal numerical scale with
whole integers, as follows: mildly better (1, 2, 3),
moderately better (4, 5, 6), or substantially better
(7, 8, 9, 10) [24].
Data Analysis
Each shoulder surgery was studied as an inde-
pendent entity. We used an analysis of variance
(ANOVA) design to analyze the data with
respect to all patients (group 1) and if a patient
received a corticosteroid injection (group 2) or
did not receive a corticosteroid injection (group
3). Pairwise comparisons between the specific
patient characteristics and types of surgery in
group 2 and group 3 were then assessed for
statistical significance using Fisher’s PLSD post
hoc test (Stat View Version 5.0, SAS Institute
Inc., Cary, NC, USA). When data sets deviated
from normality, paired comparisons were con-
ducted using a Kruskal-Wallis Z test [25, 26].
The Wilcoxon-Mann-Whitney test was used for
the ordered categorical options regarding
patient-reported outcomes after the injec-
tion(s) [27]. An alpha level of B0.05 is consid-
ered statistically significant.
RESULTS
Table 1 lists the shoulder diagnoses and the
numbers and frequencies of male and/or female
patients injected within each of the 17 diag-
nostic group/surgery groups. These data are
expressed in terms of frequencies in various
ways as shown in the column doublets (A1,2;
B1,2; C1,2). Table 1 also shows frequencies of
surgeries performed for each sex, the number of
male or female patients (injected and not
injected) as a percentage of all surgeries per-
formed, and the number of males and females
injected as a percentage of total males and
females for each of the 17 groups.
In the series of 945 total surgeries, there were
208 cases (22%) where a shoulder corticosteroid
injection was given within 6 months after sur-
gery (88 ± 38 days after surgery; range 12–-
184 days). Table 2 lists some of the patient
characteristics and the four diagnoses that were
hypothesized by the authors to be among those
that had the highest percentage of patients who
received a corticosteroid injection. Although we
found that the rate of patients receiving injec-
tions in patients who had calcific tendinitis was
the highest (40%), there were only ten patients
in this group. An equally high rate of injections
(40%) within each diagnostic/surgery group was
also found in patients who had surgery for SLAP
lesions (n = 25 patients), and all of these
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procedures were arthroscopic. Additionally,
29% of patients with adhesive capsulitis
(n = 51) had injections. Other diagnoses with
high rates of injections that are not shown in
Table 2 included isolated acromioclavicular
arthritis, which only six patients within the
diagnostic/surgery group had (33%, two
patients, injected), and patients who had
Table 2 Basic patient characteristics for all patients and the four diagnoses hypothesized by the authors to have the highest
rate of injections
Shoulder corticosteroid injection groups [group size, means, and (standard deviations)]
1 2 3 p value column 2 vs. 3
All patients Cortisone shot given No cortisone shot given
All shoulder surgeries
Number 945 208 (22%) 737 (78%) –
Age 48 (16) 46 (14) 48 (16) ns
Sex 583 M/362 F 98 M/110 F 485 M/252 F \0.001
BMI 29.2 (6.0) 28.7(6.1) 29.3 (5.9) ns
Rotator cuff repair
Number 305 58 (19%) 247 (81%) –
Age 57 (13) 53 (13) 58 (12) 0.009
Sex 189 M/116 F 32 M/26 F 157 M/90 F ns
BMI 30.5 (6.2) 29.5 (7.3) 30.7 (5.8) ns
Subacromial impingement
Number 152 42 (28%) 110 (72%) –
Age 47 (14) 45 (14) 47 (14) ns
Sex 86 M/66 F 17 M/25 F 69 M/41 F 0.03
BMI 29.2 (5.7) 28.3 (6.0) 29.6 (5.6) ns
Glenohumeral instability
Number 207 34 (16%) 173 (84%) –
Age 35 (12) 35 (12) 35 (13) ns
Sex 133 M/74 F 15 M/19 F 118 M/55 F 0.03
BMI 27.5 (5.7) 27.1 (4.9) 27.5 (5.9) ns
Calciﬁc tendinitis
Number 10 4 (40%) 6 (60%) –
Age 46 (13) 52 (19) 42 (7) ns
Sex 3 M/7 F 1 M/3 F 2 M/4 F ns
BMI 32.1 (9.2) 29.9 (6.0) 33.9 (11.5) ns
Group 1 = all patients, group 2 = patients who received a corticosteroid injection, and group 3 = patients who did not
receive a corticosteroid injection
M males, F females, ns non-signiﬁcant (p[0.05; note that p[0.1 for all ns)
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surgery for a proximal humerus fracture (24% of
21 patients injected) (Table 1 columns C, D).
Of the 208 injected cases, 8 (4%) were
insulin-dependent diabetics, 15 (7%) were
non-insulin diabetics, 110 (53%) were female,
and 98 (47%) were male. The average age and
BMI for patients receiving a corticosteroid
injection were 46 ± 14 (years) and 28.7 ± 6.1
(kg/m2), respectively. The general reasons for
the injection, as determined by the senior
author’s assessment, were: pain (63%), stiffness
(24%), and ‘‘bursitis/inflammation’’ (13%). The
percentage of patients receiving an injection
and their diagnoses are summarized in Figs. 1, 2
and Table 1.
We found significant differences (p B 0.03)
between patients who did and who did not
receive corticosteroid injections with respect to
sex (injected patients were more commonly
female) and age (younger patients were more
commonly injected after rotator cuff repair)
(Table 2). There were no significant differences
with respect to arthroscopic vs. open surgery,
BMI, or any of the other patient characteristics.
Regardless of age, sex, or diagnosis, nearly
95% of the patients (response rate 97%)
Fig. 1 Percent of injected patients’ diagnoses [number
males ? females in each diagnostic category, as shown in
the left-half of Table 1, divided by the total number of
injections (n = 208)]. AC acromioclavicular, GH gleno-
humeral, OA osteoarthritis
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reported at least mild-to-moderate improve-
ment in pain and function between 4 and
6 weeks after the injections. By 8–12 weeks after
the injections, the reports of improvements had
diminished, but unfortunately the compliance
in completing the questionnaire was only 79%.
None of the injections were associated with
major or minor complications, including no
infections, poor wound healing, dermatitis, or
any other apparent compromise of the surgery
(e.g., no association with tendon or ligament
ruptures or injuries). There were no reports that
the injection(s) made symptoms worse.
There were seven cases where corticosteroid
injections were given within 21 days of surgery.
The reason for the majority of these ‘‘early’’
injections was that these patients had high
likelihood of developing significant/recurrent
stiffness. All of these cases involved
arthroscopic capsular releases for primary
adhesive capsulitis.
In the series of 945 surgeries, there were 25
instances (3%) where it was recommended that
the patient have a shoulder corticosteroid
injection but refused to have it. Instead of
receiving injections, 13 of these patients agreed
to take an oral corticosteroid on a 1-week
tapered dosing schedule (methylprednisolone
tablets; Medrol dose pack; Pfizer Inc., NY,
USA). Similar to the injections, this course was
given between 3 weeks and 6 months after their
shoulder surgery as a means for treating their
shoulder stiffness and pain. The remaining 12
patients gave various reasons for refusing the
injection or oral corticosteroids, including eight
patients stating that they simply did not want
‘‘a shot’’ because of their concern of incurring
high pain and/or they did not want any
Fig. 2 Percent of patients in each year who received a
corticosteroid injection and their diagnoses. AC acromio-
clavicular, SA subacromial, GH glenohumeral, OA
osteoarthritis. Other less frequent diagnoses include: AC
separation, heterotopic ossiﬁcation, pectoralis rupture, and
fractures
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‘‘steroids,’’ reflecting the concern that they
could have untoward consequences [28]. The
remaining four patients were concerned with
other potential adverse reactions, including
flushing or allergic reactions. None of these 25
patients who refused the recommended injec-
tion subsequently had a corticosteroid injection
within 6 months of their shoulder surgery.
Additionally, these 25 patients were not inclu-
ded in the analysis of patients who received
injections.
Of the 208 patients who received a corticos-
teroid injection, 53 patients (25%) required a
second injection within the 6-month study
period. Of the patients requiring two injections,
30 were female and 23 were male, and the
average age was 43.2 ± 13.4 years. Pain was the
most common reason for injecting a second
time (70%), followed by stiffness (24%) and
‘‘bursitis/inflammation’’ (6%).
DISCUSSION
In our series of 945 shoulder surgeries on 754
patients, we found that the overall frequency
with which corticosteroid injections were given
within 6 months after the various non-arthro-
plasty surgeries was 22% (208/945 surgeries).
These injections were given to enhance func-
tional recovery and increase overall comfort in
patients who were experiencing excessive pain
and/or stiffness that was impeding their pro-
gress in physiotherapy. We have also found our
results to be helpful in our daily practice of
orthopedics because it provides data that help
inform our patients prior to their shoulder
surgeries of the possibility that a shoulder cor-
ticosteroid injection could be given to enhance
their postoperative recovery. For example, dur-
ing preoperative consultation the senior author
uses these data to routinely advise his patients
that there is approximately a one-in-five chance
that a corticosteroid injection will be adminis-
tered within a few months after their shoulder
surgery as a means to enhance their recovery.
This provides patients with the comfort of
knowing prospectively that the administration
of corticosteroid injections is viewed as a useful
adjunct to physiotherapy in the postoperative
setting for some patients and gives them the
opportunity to mentally prepare for the possi-
bility of this treatment modality.
The presumed effectiveness that corticos-
teroid injections have in treating postoperative
shoulder pain and stiffness was primarily based
on studies that were not conducted in the
postoperative setting. The favorable results of
many of these previous studies suggest that
significant relief of pain and stiffness would also
be gained, at least in the short term, in post-
operative patients. For example, two recent
studies show the effectiveness of corticosteroid
injections in the postoperative setting after
arthroscopic rotator cuff repair [29, 30]. One of
these studies found significant short-term
effectiveness after their patients were injected at
the time of surgery with corticosteroid into the
glenohumeral joint in the treatment group vs.
isotonic saline in a control group (50 total
patients were studied) [30]. However, in that
study, pain was only evaluated up to 24 h after
the injection, which limits comparisons with
our results. The other study is more applicable
in terms of drawing comparisons with our data
set. It that study, Shin et al. [29] evaluated 72 of
458 patients who received subacromial injec-
tions (16% injection rate) within 8 weeks of
surgery because of severe pain. They found that
pain measured on a visual analog scale
remained significantly lower at 3 months after
the injection was given. However, at that time
the patients’ functional outcomes were not
significantly different from the group that was
not injected. They found that preoperative
stiffness was a predisposing factor for persistent
pain (odds ratio, 0.2; p = 0.04). This factor was
not evaluated in the present study and warrants
additional study among the various types of
shoulder surgeries that we evaluated.
As a standard practice in the senior author’s
clinic, corticosteroid injections are not given
until 21 days after shoulder surgery even if there
was no repair or reconstruction of injured
structures. In very few of our cases were corti-
costeroid injections given within 21 days of
surgery, and in these cases there was high like-
lihood of the rapid development of stiffness
(i.e., mostly in cases of primary adhesive cap-
sulitis, as described further below). In cases
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where there was surgical repair or reconstruc-
tion, we did not give corticosteroid injections
within 12 weeks of surgery. The basis for these
injection guidelines included studies of the
effects of corticosteroids that found that: (1)
corticosteroids inhibit collagen synthesis
[31, 32], and (2) at approximately 21 days
post-operation, collagen synthesis is nearing
completion and rapid removal and new colla-
gen deposition occur simultaneously [33]. Based
on these and other studies [34, 35], which were
all prior to the 10-year study period, it was
concluded these time intervals allowed for
adequate time for healing in relation to the
spectrum of surgeries and diagnoses that might
be considered for postoperative corticosteroid
injections.
Our findings support the hypothesis that
patients with calcific tendinitis (40% of these
patients were injected), rotator cuff tears
(19%), and glenohumeral instability (16%) are
among the most likely preoperative diagnoses
to receive a postoperative corticosteroid injec-
tion (Table 2). Although 20% of insulin-de-
pendent and non-insulin dependent diabetics
combined received corticosteroid injections,
this rate is not different from that of non-dia-
betic patients (22% of these patients were
injected). This result does not indicate a higher
rate of diabetic patients refusing corticosteroid
injections because of the potential risk of these
injections to cause elevated blood glucose
levels.
Patients with SLAP lesions and calcific ten-
dinitis were the most commonly injected
groups in terms of relative percentage of cases
injected within a specific diagnostic/surgery
group (40% in each group; 4/10 calcific ten-
dinitis; 10/25 SLAP lesions). Calcific tendinitis
typically presents with severe, disabling pain,
which occurs spontaneously. There can be
concomitant stiffness, giving rise to a clinical
picture that resembles adhesive capsulitis
[36, 37]. Corticosteroid injections are often used
in the nonoperative management of this con-
dition [38, 39], which suggests that they can be
similarly used in the postoperative setting.
Patients with subacromial impingement
were also among the most commonly injected
(28%). Reasons for this might include: (1) the
bursectomy performed in these cases causes
increased inflammation and bleeding, which
can lead to stiffness and pain [40], and (2)
nearly one-half of these cases were done with a
mini-open incision, which could produce post-
operative stiffness as is seen with mini-open
rotator cuff repairs. Severud et al. [21] reported a
comparative outcome analysis between their
arthroscopic and mini-open rotator cuff repairs
and found a 14% incidence of postoperative
adhesions and stiffness in the mini-open group
and a 0% incidence in the arthroscopic group.
Consequently, it is not surprising that patients
with rotator cuff repairs were commonly injec-
ted. In fact, a recent literature review by Papalia
et al. [41] shows that excessive postoperative
stiffness after rotator cuff repair can occur in up
to 33% of cases. In turn, patients with shoulder
stiffness require a longer period of time to
achieve postoperative return of function, and
patients with severe preoperative stiffness have
a higher rate of poor outcomes after rotator cuff
repair [42, 43].
The capsular shift procedure for gleno-
humeral instability is a surgery/diagnosis that
was relatively commonly injected (16%) in our
series. These procedures can result in excessive
limitation of motion that can cause discomfort
for patients [4, 44]. For example, Antoniou et al.
[19] state that 68% of patients in their study
perceived stiffness after capsulolabral augmen-
tation. In a study of ten patients who had
internal rotation contracture after anterior
repair for recurrent dislocation of the shoulder,
MacDonald et al. [45] reported that all the
patients received pain relief and attained an
average increase of 27 degrees of rotation after
subscapularis tendon release. Although corti-
costeroid injections seem to have potential in
helping to avoid surgical lysis of contractures in
these cases, studies of the effectiveness of cor-
ticosteroid injections in this context are also
lacking.
The reasons for why repairs of SLAP lesions
had the highest rate of postoperative injections
(40%) are less clear but likely are related to the
reasons given above for capsular shift and sub-
acromial impingement procedures. This is
because SLAP repairs involve repair of the gle-
noid labrum, which is in close proximity to the
Pain Ther
glenohumeral capsule and involves instruments
being passed through the subacromial region.
Conditions such as bicipital tenosynovitis,
glenohumeral and acromioclavicular arthritis,
and rotator cuff tears can also lead to a stiff and
painful shoulder, which can mimic adhesive
capsulitis [22, 36, 46]. But patients with these
diagnoses do not have true capsular contracture
and restrictions in passive range of motion and
therefore do not have primary adhesive cap-
sulitis. Primary adhesive capsulitis may be rela-
ted to immunological, biochemical, or
hormonal imbalances and is diagnosed when
no findings on history or examination can
explain the onset of the adhesive capsulitis
symptoms [22, 46]. Secondary adhesive cap-
sulitis develops from stiffness and immobility
from previous shoulder trauma or surgery and
may represent an entirely different condition
from primary adhesive capsulitis. Most of our 51
cases with this diagnosis had secondary adhe-
sive capsulitis, where their stiffness and immo-
bility were due to excessive postoperative
stiffness from trauma or a previous shoulder
surgery, and this was a diagnosis for which
patients commonly received postoperative cor-
ticosteroid injections (29%). Although studies
of the efficacy of corticosteroid injections in
treating this condition show highly variable
outcomes, there are benefits in the short term in
terms of pain relief. We hypothesize that it is
primarily pain relief that enhances progress in
physiotherapy when patients with this problem
receive both subacromial and glenohumeral
corticosteroid injections [17, 47].
In our series of patients, we did not expect
the observed lack of differences in injection
rates for open vs. arthroscopic procedures in
view of prior studies suggesting that open pro-
cedures incur higher rates of postoperative
stiffness [2, 21, 41, 48]. However, we subse-
quently became aware of other studies showing
that stiffness can be common after arthroscopic
shoulder procedures [48–50] and that the pain
after arthroscopic and open rotator cuff repairs
is similar [51].
The fact that women were more likely than
men to receive a corticosteroid injection was
also not anticipated. This might reflect a
sex-related difference in the report of pain
intensity. This phenomenon has been observed
in several trials studying these potential differ-
ences [52–54]. This issue, as well as the finding
that younger patients with rotator cuff repairs
had higher rates of injections, warrants addi-
tional study to determine the reasons for these
findings [55, 56]. The number of patients in the
calcific tendinitis group (n = 10) was insuffi-
cient for detecting the possibility of differences
in patient characteristics including age and sex.
By contrast, there were 25 patients in the SLAP
repair group, which did not have differences in
patient characteristics and an equally high rate
of injection compared to calcific tendinitis.
Major and minor complications resulting
from shoulder corticosteroid injections are
reviewed by Gruson et al. [5]. One of the major
risks is the potential for causing an infection
from the corticosteroid injection. There were
no infections in any of the patients in our
study, which suggests that our skin prep with
alcohol followed by povidone-iodine is
sufficient.
Limitations of our study include the lack of
evaluator blinding, which can introduce bias,
and a main outcome measure (symptom chan-
ges) was only assessed in the intervention (in-
jection) group with no similar follow-up of a
control (no injection) group. Each surgery was
also analyzed as an independent entity and
without any particular consideration for
potential inter-subject variation in baseline pain
perception or pre-existing propensity for
shoulder stiffness in all patients (not just in
those with adhesive capsulitis). Future studies
that are designed to address these limitations
and related issues that are inherent in retro-
spective studies are needed in order to deter-
mine the effectiveness of these injections in
enhancing functional recovery after
non-arthroplasty shoulder surgeries.
CONCLUSIONS
Our 10-year retrospective view of the senior
author’s practice shows that approximately one
in five patients (22%) received a subacromial
and/or glenohumeral corticosteroid injection
within 6 months following their
Pain Ther
non-arthroplasty shoulder surgery. Among the
diagnoses with more than ten patients who had
the highest percentages of patients who
received an injection were calcific tendinitis
(40%), SLAP lesions (40%), adhesive capsulitis
(29%), subacromial impingement (28%), proxi-
mal humerus fracture (24%), rotator cuff tear
(19%), and glenohumeral instability (16%).
There were no significant differences with
respect to arthroscopic vs. open surgery, BMI, or
any of the other patient characteristics. In
addition to achieving the main goal of estab-
lishing our frequency of shoulder corticosteroid
injections in the postoperative setting, the pre-
sent study also provides valuable information
for incorporating their use into physiotherapy
protocols that can be systematically studied.
These future studies must have alternative
treatment groups and serial follow-up visits
with validated outcome measures. The present
study represents an important first step toward
achieving these broader goals.
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